Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study

Breast Cancer Research and Treatment

Volumn 147, Issue 2, 2014, Pages 415-421

  Allott, E H ^a,b   Tse, C K ^b   Olshan, A F ^a,b   Carey, L A ^a,c   Moorman, P G ^d   Troester, M A ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer specific mortality; Duration; Estrogen receptor; Non steroidal anti inflammatory drugs; Regularity

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTHRITIS; ARTICLE; BREAST CANCER; BURSITIS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EPIDEMIOLOGICAL DATA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN SYNTHESIS; FEMALE; HEADACHE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MENSTRUATION DISORDER; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; RHEUMATIC DISEASE; SELF REPORT; TREATMENT DURATION; TUMOR INVASION; TUMOR VOLUME;

EID: 85027939678     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3099-z     Document Type: Article

References (37)

1. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84:1188–1192
2. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3(1):28
3. Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100:1439–1447
4. Bosetti C, Rosato V, Gallus S et al (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23:1403–1415
5. Luo T, Yan HM, He P et al (2012) Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 131:581–587
6. Moorman PG, Grubber JM, Millikan RC et al (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14:915–922
7. Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 29:2433–2440
8. Marshall SF, Bernstein L, Anton-Culver H et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805–812
9. Gill JK, Maskarinec G, Wilkens LR et al (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166:1150–1158
10. Gierach GL, Lacey JV Jr, Schatzkin A et al (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10:R38
11. Howe LR, Subbaramaiah K, Brown AM et al (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8:97–114
12. Zhao Y, Agarwal VR, Mendelson CR et al (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739–5742
13. Holmes MD, Chen WY, Li L et al (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28:1467–1472
14. Blair CK, Sweeney C, Anderson KE et al (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101:191–197
15. Wernli KJ, Hampton JM, Trentham-Dietz A et al (2011) Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 20:131–137
16. Li Y, Brasky TM, Nie J et al (2012) Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomark Prev 21:239–242
17. Newman B, Moorman PG, Millikan R et al (1995) The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 35:51–60
18. O’Brien KM, Cole SR, Tse CK et al (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110
19. Liu CH, Chang SH, Narko K et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563–18569
20. Chang SH, Liu CH, Conway R et al (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101:591–596
21. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181–193
22. Hwang D, Scollard D, Byrne J et al (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455–460
23. Ristimaki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632–635
24. Hudson AG, Gierach GL, Modugno F et al (2008) Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomark Prev 17:680–687
25. Kirsh VA, Kreiger N, Cotterchio M et al (2007) Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 166:709–716
26. Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55
27. Zhang Y, Coogan PF, Palmer JR et al (2005) Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 162:165–170
28. Jacobs EJ, Thun MJ, Connell CJ et al (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomark Prev 14:261–264
29. Brasky TM, Bonner MR, Moysich KB et al (2011) Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 22:965–975
30. Zhang SM, Cook NR, Manson JE et al (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98:989–991
31. Bardia A, Olson JE, Vachon CM et al (2011) Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 126:149–155
32. Patterson RE, Flatt SW, Saquib N et al (2010) Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat 122:859–865
33. Ji J, Liu X, Sundquist K et al (2011) Survival of cancer in patients with rheumatoid arthritis: a follow-up study in Sweden of patients hospitalized with rheumatoid arthritis 1 year before diagnosis of cancer. Rheumatology (Oxford) 50:1513–1518
34. Chow LW, Yip AY, Loo WT et al (2008) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111:13–17
35. Lustberg MB, Povoski SP, Zhao W et al (2011) Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer 11:221–227
36. Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102
37. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080